Human Reproduction Update Advance Access originally published online on November 29, 2004
Human Reproduction Update 2005 11(1):69-89; doi:10.1093/humupd/dmh052
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing
Department of Obstetrics and Gynaecology, Reproductive Medicine Unit, Elizabeth Garrett Anderson and Obstetric Hospital, University College London Hospital, Huntley Street, London WC1E 6DH, UK
1 To whom correspondence should be addressed. Email: k.lutchman-singh{at}ucl.ac.uk
The improved long-term survival of adolescents and young women treated for cancer has resulted in an increased focus on the effects of chemotherapy on ovarian function and its preservation. These women may seek advice and treatment regarding their reproductive status, including ways of preserving their fertility and preventing a premature menopause—factors that can have a profound impact on their quality of life. This article comprehensively reviews ovarian reserve testing (ORT) in general. Special emphasis is placed on patients with cancer, including the pathophysiology of gonadal damage following chemotherapy, fertility preservation and the potential role of ORT. Baseline parameters of ovarian reserve [FSH LH, estradiol, inhibin B and anti-Müllerian hormone (AMH)] have not yet performed sufficiently well in predicting poor outcome in assisted reproduction, but biochemical markers of ovarian reserve appear to be better than chronological age. Inhibin B and AMH show potential for future use. Dynamic testing appears to show much promise, especially stimulated levels of inhibin B and estradiol. The most promising tests of ovarian reserve are the biophysical markers, where total antral follicle count was found to be most discriminatory followed by ovarian volume. Combination of biochemical, biophysical and clinical markers of ovarian reserve may also improve predictive capacity. However, there is a lack of data pertinent to ORT in cancer. As yet there is no single clinically useful test to predict ovarian reserve accurately. Patients with cancer represent a distinct cohort who have particular concerns about their future fertility and the possibility of a premature menopause, they can benefit greatly from knowledge of their functional ovarian reserve. Large, prospective, randomized, adequately controlled studies specific to different geographical areas are required in a control population of comparable reproductive age to determine the potential role of ORT in clinical practice.
Key words: cancer / chemotherapy / fertility / ovarian reserve tests / premature menopause
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Yeh, Beom Su Kim, J. Peresie, and C. Page Declines in Levels of Hyperpolarization-Activated Cation (HCN) Channels in the Rat Ovary After Cisplatin Exposure Reproductive Sciences, October 1, 2009; 16(10): 986 - 994. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Hickey, M. Peate, C.M. Saunders, and M. Friedlander Breast cancer in young women and its impact on reproductive function Hum. Reprod. Update, May 1, 2009; 15(3): 323 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Cocco, C Sardu, P Gallo, R Capra, M. Amato, M Trojano, A Uccelli, M. Marrosu, and the FEMIMS group* Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study Multiple Sclerosis, November 1, 2008; 14(9): 1225 - 1233. [Abstract] [PDF]
|
|
|
|
|
|
R. Beck-Fruchter, A. Weiss, and E. Shalev GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data Hum. Reprod. Update, November 1, 2008; 14(6): 553 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Blumenfeld and M. von Wolff GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy Hum. Reprod. Update, November 1, 2008; 14(6): 543 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, and V. Stearns Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer Ann. Onc., October 1, 2008; 19(10): 1669 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Donnez, M.M. Dolmans, C. Pirard, A. Van Langendonckt, D. Demylle, P. Jadoul, and J. Squifflet Allograft of ovarian cortex between two genetically non-identical sisters: Case Report Hum. Reprod., October 1, 2007; 22(10): 2653 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Blumenfeld How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries Oncologist, September 1, 2007; 12(9): 1044 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ives, C. Saunders, M. Bulsara, and J. Semmens Pregnancy after breast cancer: population based study BMJ, January 27, 2007; 334(7586): 194 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Donnez, B. Martinez-Madrid, P. Jadoul, A. Van Langendonckt, D. Demylle, and M.-M. Dolmans Ovarian tissue cryopreservation and transplantation: a review Hum. Reprod. Update, September 1, 2006; 12(5): 519 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Oktay, O. Oktem, A. Reh, and L. Vahdat Measuring the Impact of Chemotherapy on Fertility in Women With Breast Cancer J. Clin. Oncol., August 20, 2006; 24(24): 4044 - 4046. [Full Text] [PDF]
|
|
|
|
|
|
I. E. Smith, M. Dowsett, Y.-S. Yap, G. Walsh, P. E. Lonning, R. J. Santen, and D. Hayes Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines J. Clin. Oncol., June 1, 2006; 24(16): 2444 - 2447. [Abstract] [Full Text] [PDF]
|
|